16 November 2011

Tata Motors - "A trade-off between domestic margins and global volumes" ::LKP

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Domestic business disappoints, while JLR saves the game again
Tata Motors consolidated sales was up by 26% yoy in Q2 FY12, led by strong sales performance on the JLR business. JLR volumes grew by 23.3% yoy to 68000 units, while EBITDA margins were at 14.92%a decline of 170 bps yoy. Standalone sales were up by 13% yoy and 9% qoq, as volumes grew by 4%, driven by LCV segment as PV segment continued to decline.Consolidated margins came in at 12.5% while standalone margins sunk to 7.2%, lowest in the recent past. Adverse product mix, high RM costs, higher incentives on the PV side, declining PV business and  few price hikes led to margins in domestic business to fall. In the quarter, the company incurred forex losses to the tune of Rs4390mn, in totality out of which Rs 2490mn came in the domestic business.This was due to adverse GBP/$ and INR/$ movements. Excluding these losses, adjusted standalone PAT was down by just 8% yoy and flattish qoq, while consolidated adjusted PAT was up 10.6% yoy.
JLR volumes to remain buoyant on Evoque and emerging economies
JLR sold ~130,000 units in the first half of the year driven by China and other developing countries like Brazil, Russia and Middle East. Contribution from China has gone up from 9.7% in Q2 FY11 to 16% in Q2 FY12 and the absolute volumes have doubled in the same period. With the launch of Evoque which has still order bookings close to 20,000 has started showing its impact in the volumes of JLR (wholesale volumes of 7772 units in Q2). With Evoque expected to form 15-20% of volumes in FY13E, we expect a strong growth in JLR volumes going forward. Traction happening in the emerging markets and steady performance in the US will be able to offset any weakness in the European continent and UK. Application of smaller diesel engines in Jaguar vehicles will also lead to volume improvement, for e.g. Jaguar XF model launched in July is receiving a good response. We expect JLR to report 269K units in FY12E and 303K in F 2013E.
Domestic LCV volumes to remain strong while PVs may continue to disappoint
On the domestic front, CV sales are expected to hold up in the rest of the year as well. In difficult operating environment especially in South India, MHCV sales were up 5% in H1 FY12, while LCV sales were up by 23% in the same period. Going forward, we expect MHCV sales to hold up on issues in South Indian markets getting resolved. On the LCV front, the demand for Tata Ace family is expected to remain robust.Increasing capacities for Tata Ace at Dharwad facility will keep pace with the rising demand for the model.However, with macro environment getting worsened for PV industry, Tata Motors with a relatively aged and a weak product portfolio will continue to underperform. This may pull down the domestic volumes. Nano also has been unsuccessful and is not meeting company’s expectations. We expect MHCV/LCV/PV to grow by 6.5%/16%/-12.1% in FY 12E and 7%/12%/9.5% in FY 13E respectively.
Domestic margins to be a drag on the stock
Deceleration of domestic margins to 7.2% may not be the bottoming out of domestic margins as indicated by the management. Higher raw material costs, higher incentives on PVs and lower utilization of PV capacities have resulted in such margins.Going forward, management has cautioned us for pressure on domestic margin performance. We believe that Tata Motors cannot improve the PV capacity utilization rates as PV demand is expected to report a negative growth this year. Some positive impact of RM costs softening may be seen in the ensuing quarters, but they won’t be enough if there is absence of operating leverage from PVs. Ramp up of capacities on LCV side at Dharwad will also support margins as capacity utilization goes up (Ace manufacturing facilities function at more than 100% capacity utilization).
On JLR side, rising Evoque volumes may spoil the product mix, but, China which is having extremely high realizations may take care of that. Also, Evoque will be priced differentially depending upon the geographies and may not result into the expected margin distortion. Higher utilization of capacities with growing volumes will offer operating leverage. Hence, we are maintaining our margins on JLR business at 13.7%/14.3% in FY 12E/FY 13E. Due to the concerns at domestic business, we are slightly cutting down our margin estimates in domestic markets to 8.3%/8.5% in FY 12E/13E. Hence, our consol margins now lie at 11.7%/12.2% respectively for FY 12E/FY 13E post cutting them by 60/40 bps respectively.
Outlook and valuation
Though we have cut our margin estimates for domestic business, we are maintaining the same for JLR and are estimating higher volume growth for JLR. The net impact of this has led us to increase our target price for Tata Motors to Rs 195, from our previous target of Rs172, which got achieved recently. However, from current levels of Rs181, we see a limited upside of 8%. We arrive at our target price by deriving a value of Rs 84 for domestic business, Rs131 for JLR and Rs19 for other subsidiaries .

BSE, Bulk deals

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Deal DateScrip CodeCompanyClient NameDeal Type *QuantityPrice **
16/11/2011531247Alpha HitechMUKHTYARBEGUM NOORMIYAN SHAIKHS253625.46
16/11/2011590006Amrutanjan Health-$CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDB18430698.92
16/11/2011590006Amrutanjan Health-$A K G SECURITIES AND CONSULTANCY LTDB20033699.10
16/11/2011590006Amrutanjan Health-$A K G SECURITIES AND CONSULTANCY LTDS20033699.19
16/11/2011590006Amrutanjan Health-$CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDS18430695.23
16/11/2011524760Arvind Intl-$DINESH CHANDRA BAJORIAB10000013.56
16/11/2011524760Arvind Intl-$ANUPAMA BAJORIAB10000013.66
16/11/2011530881Century TwntySAMBA SIVA RAO RAVURIB160009.50

NSE, Bulk deals, 16-Nov-2011

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


DateSymbolSecurity NameClient NameBuy / SellQuantity TradedTrade Price /
Wght. Avg.
Price
Remarks
16-Nov-2011AMRUTANJANAmrutajan Health LtdCROSSEAS CAPITAL SERVICES PVT. LTD.BUY18,430694.58-
16-Nov-2011AMRUTANJANAmrutajan Health LtdCROSSEAS CAPITAL SERVICES PVT. LTD.SELL18,430698.76-
16-Nov-2011EVERONNEveronn Education LimitedCHANDARANA INTERMEDIARIES BROKERS P. LTDBUY1,01,532323.20-
16-Nov-2011EVERONNEveronn Education LimitedCHANDARANA INTERMEDIARIES BROKERS P. LTDSELL1,01,532321.76-
16-Nov-2011EVERONNEveronn Education LimitedCROSSEAS CAPITAL SERVICES PVT. LTD.BUY1,44,828321.05-
16-Nov-2011EVERONNEveronn Education LimitedCROSSEAS CAPITAL SERVICES PVT. LTD.SELL1,44,828320.60-
16-Nov-2011GANESHHOUCGanesh Housing Corp LtdTHE ROYAL BANK OF SCOTLAND N.V LONDON BRANCHSELL2,35,000114.00-

16/11/11: Categories Turnover (Rs. crore) Clients NRI Proprietary Trade Data

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



Categories Turnover
(Rs. crore)
ClientsNRIProprietary
Trade DateBuySalesNetBuySalesNetBuySalesNet
16/11/111,736.181,675.1261.060.770.340.43522.61505.2217.39
15/11/111,556.931,524.5332.400.590.240.35441.65463.68-22.03
14/11/111,555.711,574.87-19.150.630.570.06422.62441.28-18.66
Nov , 1116,108.4115,975.91132.508.346.361.984,604.224,617.68-13.46
Since 1/1/11429,326.66433,924.80-4,598.14304.98212.0292.96124,904.85124,082.22822.63

16/11/11:: FII & DII Turnover (BSE + NSE) (Rs. crore)

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


FII & DII Turnover (BSE + NSE)
(Rs. crore)
FIIDII
Trade DateBuySalesNetBuySalesNet
16/11/111,743.782,232.67-488.891,374.111,096.32277.79
15/11/111,698.842,108.61-409.77989.22783.26205.96
14/11/112,542.992,221.37321.62862.44871.74-9.30
Nov , 1120,536.8220,066.17470.658,767.309,824.16-1,056.86
Since 1/1/11   *539,935.67557,442.26-17,506.59251,034.14230,045.5020,988.64

FII DERIVATIVES STATISTICS FOR 16-Nov-2011

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


FII DERIVATIVES STATISTICS FOR 16-Nov-2011 
 BUYSELLOPEN INTEREST AT THE END OF THE DAY 
 No. of contractsAmt in CroresNo. of contractsAmt in CroresNo. of contractsAmt in Crores 
INDEX FUTURES1097032723.541423673551.1160049114927.71-827.57
INDEX OPTIONS97678524491.3492333123262.90183895046253.601228.44
STOCK FUTURES1320853231.421385193357.51125624429088.24-126.09
STOCK OPTIONS24132563.4323761554.1041593985.779.32
      Total284.10


-- 

India may still be insulated from global crisis but recovery challenging: Moody's

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



In an interview with ET Now, Atsi Sheth, VP-Sovereign Risk Group, Moody's, talks about the larger outlook for the Indian economy and various other parameters. Excerpts:

We did see the rupee breaching the 50 levels. In fact, it is closer to 51 as we speak. Would you say that you would look to revisit your ratings as far as the Indian economy goes, especially on the current account deficit front given the fairly weak macroeconomic outlook?

When a country's currency depreciates, it could be for a variety of reasons. It could be because the current account deficit is widening as it is in India, which means that importers are demanding more foreign currency and exporters are not earning as much foreign currency, and the other reason could be that portfolio flows which tend to raise the value of your currency when they are coming in strong are weak right now. So those are the two reasons that are leading to a decline in the value of the rupee.

One is global risk aversion, which has not specific to India but really things happening around the world, and the other is the fact that India's growth is domestic demand driven and hence import growth tends to be stronger than export growth in the best of times and in the worst of times.

Since this is already something that has been incorporated into rating, I do not think depreciation in the rupee for those reasons would be reason to change our outlook on the rating. If, however, we found that the depreciation is because of other reasons that are recognition that the structural profile of growth in India is in trouble, then we would start being concerned. But at this point we really think that the depreciation is cyclical given by global factors and not due to some problems in India's long-term growth profile.

Just but just want to get you a sense of what you make of the contagion effect of the Eurozone fallout on emerging markets particularly India?

During the last global financial crisis, that was in 2008-2009, people found that India was relatively insulated from the global growth downturn. Growth did a little bit less than it did in other emerging markets and it recovered a lot faster than it did around the world. So India was insulated. The question now is now that as we are going through another global growth downturn, will India remain as insulated? And to answer that you really need to take into account three things. Two things are different than they were in 2008 and one thing is the same.

Of the two things that are different, the first is fiscal policy. In 2008 the budget deficit was much narrower then it is now actually and so the government was able to stimulate its way to growth. It was able to cut taxes a little bit, it was able to spend a little bit more and so fiscal stimulus really helped growth and the recovery in growth that is not the case now. The fiscal deficit is already wide, the government is trying to actually narrow it. So perhaps that kind of fiscal stimulus cannot be expected this time around.

The second difference was that business confidence in India was quite high in 2008 and global business confidence towards India was also quite high in 2008, that seems not to be the case now. If you ask people around the country, you get the sense that business confidence is actually quite low and people are looking for ways to recover this business confidence, but not finding it. Similarly global attitudes towards India have taken a little bit of a hit over the last year I think thanks to corruption scandals, thanks to sort of there are not being any policy impetus to invite for an investment.

So that is the other thing that is different between 2008 and now which makes recovery that much more difficult. There is one similarity in 2008 monetary policy was very tight, interest were high so simply by lowering interest rates you could trigger a recovery, you could bring down borrowing cost for consumers, you brought down borrowing cost for investors and that is what led to a recovery.


This time around I feel it is the same thing that is going to happen. We hear that monetary policy has peaked. It probably has, and if indeed rates start to decline over the next year, I think this time next year you will probably see both consumption and business investment recovering. So India is perhaps still insulated because it does not depend as much on exports for its own growth, but the fact that its domestic demand is still dependent on a little bit of fiscal stimulus and business confidence, that might make the recovery a little more challenging this time around.

How much worse do you believe the fiscal deficit can get against the projected 4.6% of GDP and again what is the sort of tax revenue growth that you are pencilling in?

The fiscal deficit is targeted at 4.6% and the consensus now is that target is not going to be met and we agree with consensus on that. Again the consensus view is that the actual deficit will be somewhere between 5% of GDP and 5.5% of GDP and we have no reasons to disagree dramatically with that assessment. So we do think the target will be missed and this means that borrowing cost will probably stay high for the government in the near term.

In terms of revenue growth, in India revenue growth is co-related with the way the nominal GDP grows and more importantly the way profits and wages grow because that is how your corporate income tax comes in and at the beginning of the year people had simply assumed a higher rate of GDP growth which assumed a higher rate of profitability that has not turned out to be true. So we do expect that the revenue targets as well will be missed.

Just a final question then do you see the downside risk to GDP forecast of around 7.5% for FY12 still now that the monetary tightening is widely expected to be at its peak?

There is always a downside risk to GDP growth when you see global growth being revised down again and again as we are seeing now and also the fact that we talked earlier about business confidence that business confidence has yet to recover. So given that yes there is some downside risk. We have already seen the high frequency data which is the PMI data that comes out, the IIP data that comes out. That shows that particularly manufacturing is feeling the brunt of this tightening monetary policy.
So yes, there is a mild downside risk. From a sovereign rating perspective, do we worry inordinately about it? No. I would say if growth is a tad lower than say 7% or 7.5%, I do not think that changes our view that in the long term. India actually has the growth potential and will continue to retain that growth potential, thanks to its demographics, thanks to the existence of an entrepreneurial spirit and thanks to savings rate that is able to fund that growth. So those three things have not really changed.

IDFC -management to achieve profit growth at 18% CAGR over FY11-13E ::ICICI Securities

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


P A T   s u r g e s   o n   a c c o u nt   o f   o t h e r   i n c o m e …
IDFC’s core performance was in line with estimates but non-interest
income witnessed a surge of 45% YoY to | 393 crore, thereby supporting
55% YoY growth in PAT to | 524.7 crore (I-direct estimate: | 308.8 crore).
NII grew 33.2% YoY to | 498 crore in line with estimates on account of a
10 bps improvement in NIM to 4%.  Loan book growth was, however,
subdued (up 14.3% YoY vs. our estimate of 18% growth). Asset quality
was stable with absolute GNPA maintained at | 77.6 crore and GNPA ratio
at 0.2%. Provisions came in line with estimates at | 63 crore. We believe
the ongoing stress on the infrastructure sector could pressurise asset
quality. Hence, we have revised our PAT estimates from | 1858 crore to |
1794 crore (18% CAGR over FY11-13E).
ƒ Principal investment boosts profitability...
Non-interest income increased from | 122 crore in Q1FY12 to | 393
crore in Q2FY12 on the back of a sharp rise in income from principal
investment worth | 243 crore. Profit worth | 240 crore was booked
on account of ~1.1% NSE stake sale. However, if we exclude
principal investment, non-interest income has seen a 42% YoY drop
on account of a fall in investment banking fees. Proportion of noninterest income in total income was high at 44% due to this one-off.
We expect proportion of non-interest income at 30% for FY13E.
ƒ Loan book growth to remain under pressure….
The loan book grew 14.3% to | 39313 crore, which was lower than
our estimate of | 40589 crore. The major culprit for this slowdown
was de-growth of 3% YoY in the  corporate loan book to | 14307
crore. Considering the gloomy atmosphere in the infrastructure
sector, we have estimated conservative growth of 15.4% in the loan
book to | 43463 crore for FY12E.
V a l u a t i o n
We expect the management to achieve profit growth at 18% CAGR over
FY11-13E to | 1794 crore. Although asset quality has been healthy so far,
stress on the infrastructure sector could impact NPA, which is weighing
on valuations. Return ratios were strong in Q2FY12 with RoA of 4.1% and
RoE of 12.7%. We expect this to remain healthy at RoA of 2.9% and RoE
of 13.8% for FY13E.

Power Grid Corporation of India (Overweight): Positive data-points from Sep-q analyst meet ::JP Morgan

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



Mr. R.N. Nayak, CMD accompanied by senior management of PGCIL
addressed the analyst meet yesterday. The key takeaway was that the
momentum in capitalization seen in Sep-q has continued in the month of
October. So far in FY12, Rs51bn of transmission projects have been
commissioned. Of this ~Rs32.3bn was added to gross block in Sep-q and
~Rs10bn in October so far. Management did not give guidance on
capitalization but they seemed confident that the pick-up is likely to sustain.
We do not see any downside to our Rs98bn capitalization estimate in FY12.
For details on Sep-q results and our OW investment view on the stock see our
last note: "PAT adjusted for notional FX loss ahead of consensus, pick up in
capitalization on expected lines”
 Capex guidance for FY12 maintained. So far in FY12 PGCIL has
incurred Rs49bn of capex. Management is confident of a pick-up in balance
5months of the fiscal to achieve full-year target of Rs176bn and thus meet
11th Plan (FY08-12) target of Rs550bn. In our view, the capex guidance
appears challenging and we have maintained est. of Rs140bn capex in
FY12.
 Contract awards by PGCIL have gone up sharply in Oct-11: According
to management, so far in current fiscal Rs78.26bn of contract awards have
been completed, of which Rs36bn awards have been done in the current
month till date.
 Contract pipeline implies pick up in 2HFY12: As per management
Rs138bn of tenders are out. Bids have to be opened for Rs85bn of contracts
in next 45 days and awards are likely over next 3-4months. During 1HFY12
~64% of contracts were awarded to transmission tower EPC players or
conductor suppliers. In 2HFY12 besides a pick up in contract awards by
PGCIL we expect the share of awards to substation equipment suppliers to
play catch up.
 SEB debtors. According to management ~Rs5.33bn of receivables (of total
sundry debtors of Rs25.6bn) was over 60days normative payment cycle.
Management does not foresee default by any SEB and extensions to make
payment have been allowed to certain states post discussions in lieu of
PGCIL’s long standing relationship with such customers (SEBs). Investor
concerns had arisen from PGCIL's annual report disclosure on payment
delays (beyond 60days) in few pockets viz. Delhi, Daman & Diu and certain
North Eastern states.

Sell Nitin Fire; Target :Rs 30 ::ICICI Securities

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


V a  l u a t i o n s   s t r e t c  h e  d …
Nitin Fire’s (NFPIL) Q2FY12 results were in line with our estimates as net
sales witnessed a 6.7% de-growth on the back of the muted performance
of the domestic business. Net sales  stood at | 145.2 crore as against |
155.5 crore in Q2FY11. EBITDA margins for the company improved YoY
from 13.5% to 15.7%. Employee cost as a percentage of sales improved
from ~5% to ~3% while rationalisation of other expenditure from 8.5%
to 7.5% also resulted in higher margins for the company. Net profit grew
24.3% to | 17.1 crore on the back of higher EBITDA led by lower cost.
ƒ Standalone performance review
On a standalone basis, sales stood at | 26.5 crore, de-growth of 45.6%.
The raw material cost has declined from | 41.1 crore to | 19.1 crore.
Employee cost has gone up from | 0.92 crore to | 1.53 crore while other
expenditure increased from | 1.5 crore to | 2.5 crore. Net profit declined
from | 4.3 crore to | 2.2 crore. Despite higher EBITDA, NFPIL has posted a
dip in net profit due to lower other income and increase in tax liability.
ƒ Sales break-up  
During the quarter, NFPIL’s domestic sales witnessed de-growth of 19.0%
to | 27.1 crore from | 33.4 crore in Q2FY11. Consequently, the
international business also witnessed a 3.3% de-growth to | 118.1 crore
compared to | 122.1 crore in the corresponding quarter.
V a l u a t i o n
At the CMP, the stock is trading at 15.4x and 14.5x its FY12E and FY13E
EPS of | 2.4 and | 2.6, respectively. Though the company has posted two
consecutive quarters of strong results on the back of strong results from
the fire fighting business, we believe the stock is expensively valued after
the run up in the last six months. We recommend investors book profit in
the stock and exit at current levels. We are  terminating coverage on the
stock due to lack of operational information.

Kotak Mahindra Bank (Overweight): Strong numbers from the parent bank ::JP Morgan

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Kotak Mahindra Bank reported Rs 4.32bn consolidated PAT, up 18% y/y
The standalone bank reported exceptionally strong PAT growth (34% y/y)
but the performances of the subsidiaries were mixed – the 4x y/y growth in
life insurance supporting the consolidated numbers.
 Robust loan growth, NIM pressures. Loan growth continued to be
strong (35% consolidated) with the corporate book growing 30% q/q.
This derisking squeezed NIMs to 4.8% (5% in 1Q) - weak current
account balances also contributed. Management guided full-year loan
growth at ~30%, implying 6% growth in 2H – we think that’s modest,
even when seasonally adjusted.
 Credit costs near-zero. Consolidated credit costs were ~20bp
(annualized), continuing the momentum of 1Q. The bank is seeing
recoveries of past bad loans, which is offsetting incremental delinquency
and the resumption of general provisioning. While these low levels may
not sustain, we see no significant credit quality shock, given Kotak's mix
of low-yield corporate and retail loans.
 Insurance props up the subs. The subsidiary performance was weak.
Capital markets now contribute a mere 6% of PBT and the IB sub
actually reported losses. The life insurance company reported strong
profits (up 4x y/y) on the back of cost-cutting – profits tend to seasonally
rise in 2H given the lumpiness in 4Q revenues.
 Maintain OW. Kotak is one of our top picks – we see the banking
business continuing to grow very strongly and the subsidiaries are
becoming less relevant as the quarters progress. Moderating NIMs are a
concern, but we think they’ll stabilize around the time credit costs
bottom out.

Hold Elder Pharmaceuticals; Target :Rs 428 ::ICICI Securities

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


R e s u l t s   i n   l i n e ,   m a r g i n  p r e s s u r e   p e r s i s t s …
Elder Pharmaceutical’s Q2FY12 results were in line with our estimates. On
a like-to-like basis, the results are not comparable as the company
increased its stake in Biomeda and completed the acquisition of
NeutraHealth. Net sales increased by 57.2% YoY to | 331.1 crore in line
with our expectation of | 327 crore,  driven by growth across therapies.
Excluding sales from Biomeda and NeutraHealth, the standalone sales
increased by 24% YoY to | 252.8 crore. Therapies like women’s
healthcare, neutraceuticals, anti-infectives, lifestyle diseases and pain
management posted growth of 18.9%, 19%, 16%, 20% and 30%,
respectively. EBITDA margins declined 330 bps YoY to 16.5% mainly due
to consolidation of Biomeda and NeutraHealth. Both depreciation and
interest cost increased by 21% to  | 9 crore and 42% to | 21.2 crore,
respectively, on the back of commission of the Cephalosporin block at the
Langa road facility and hike in lending  rates. Thanks to lower tax rate of
24.4%,  the  net  profit  grew  by  41.5%  to  |  19.4  crore.  We  have  increased
the target price on the back of an upbeat performance.
ƒ Plans to launch eight products in second half
The company launched four drugs during the quarter taking the total
product launches in the first half to  eight. It is planning to launch
eight to 10 products in the second half.
ƒ New proposed pricing policy not to have much impact
Currently, Elder’s two brands are in the DPCO list, which accounted
for 4-5% of total sales. As per the proposed new pricing policy,
around 6-7% of total sales will come under the purview of price
control. According to the management, the Shelcal group (annual
sales: ~| 160-180 crore) would not come under the new proposed
pricing policy as calcium carbonate from oyster shell has not been
covered in pricing list while plain Calcium carbonate is covered.
V a l u a t i o n
We expect Elder’s sales and PAT to grow at a CAGR of 24.7% and 39.8%,
respectively, during FY11-13E. Other than leading legacy brands, the
performances of Biomeda and NeutraHealth will weigh on valuations. We
have ascribed a target price of | 428, based on 7x FY13E EPS of | 61.1.

Dr. Reddy's Laboratories: 2Q Results: Strong US Generics and PSAI drive growth ::JP Morgan

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


DRRD reported strong Q2FY12 earnings driven by US generics and PSAI
business. US product launch pipeline appears robust, which together with Russia
should support growth in 2H. Growth in India remains muted and Europe
continues to de-grow on German tenders. PSAI growth picked up in 2Q after tepid
1Q and management expects the rate to sustain going forward in 2H and FY13.
 US and PSAI drive Q2 growth. NA generic revenues increased 42% YoY
driven primarily by new launches (5 new products launched in 2Q), including
limited competition products such as fondaparinux and fexofenadine
pseudoephedrine D24 OTC. Management noted that increased market share in
certain key products has also aided growth. With US launch of (180-day
exclusivity) Olanzapine 20 mg (US$900MM market size) in 3Q, DRRD US
product pipeline appears robust and should support the revenue growth for the
2H. PSAI business revenues increased 29% YoY led by new product launches
in Europe and improved customer order book for Pharma services.
 Pricing pressure in Germany, growth in India remains tepid. European
generics revenues declined 11% YoY with Germany (-27%, adverse impact
from tender business) offsetting 26% growth rate in Rest of Europe (new
launches in UK, growth in out-licensing). Russia/CIS grew 23% YoY driven by
increase in OTC products portfolio. Indian business growth remained subdued
at 10% YoY, tracking below market growth rates. Management indicated that
the sales force re-alignment disrupted domestic sales in 2Q, and expects to see
enhanced sales force productivity going forward.
 Q2FY12 result highlights. Revenues up 21% YoY driven by strong growth in
US Generics (+42% YoY), Russia/CIS (+23% YoY) and Europe PSAI business
(+49% YoY). Gross margins improved 40bp YoY (Global Generics gross
margins -100bp YoY, PSAI gross margins +420bp YoY). Adj. EBITDA
margins declined 30bps YoY on higher S,G&A costs (+130bp YoY). Net profits
+7% YoY pared by higher depreciation and taxes.
 Maintain Neutral. DRRD stock currently trades at 24.2x FY12E P/E and 19.7x
FY13E P/E, which we believe are fair valuations pricing in growth opportunities
to FY14. Remain N with Mar-12 TP of Rs1600. Key upside risks include new
big-ticket product approvals in the US, pick-up in domestic growth and steep
ramp-up of GSK alliance. Key downside risks include potential regulatory
issues, delays in US launches, and a protracted growth slowdown in India